Abstract
The Australian Streptokinase Trial (ASK) Study was begun in June 1992 as an Australia-wide effort to assess the efficacy of intravenous streptokinase as a thrombolytic agent to minimize morbidity and mortality after acute ischemic stroke. The study was preceded by a pilot study of 52 patients among seven centers to assess the practicality of administering an agent within a 4-h time window in Australian hospitals. The results of the pilot study suggested that a major study was practical and that a thrombolytic agent administered acutely to patients with ischemic stroke was safe.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Tokyo
About this paper
Cite this paper
Dorman, G.A. et al. (1995). Australian Streptokinase Trial: Progress Report. In: Yamaguchi, T., Mori, E., Minematsu, K., del Zoppo, G.J. (eds) Thrombolytic Therapy in Acute Ischemic Stroke III. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68459-6_25
Download citation
DOI: https://doi.org/10.1007/978-4-431-68459-6_25
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-70139-2
Online ISBN: 978-4-431-68459-6
eBook Packages: Springer Book Archive